Press release

Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22

-The company shares videos each day of the week to raise awareness about mitochondrial disease and to highlight ongoing activities at Abliva-

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, participates in World Mitochondrial Disease Week 2024, which takes place on September 16 – 22, 2024. The theme this year is ‘Illuminate Tomorrow: Revitalise your energy’. The week aims to increase global awareness and understanding of the disease. During the week, Abliva will share short videos each day highlighting the ongoing activities at Abliva.

It is estimated that about 1 in 5,000 people today live with mitochondrial disease, a severe and debilitating disease that often affects many of the organ systems. The disease manifests differently across patients with some developing the disease as a child, while others are diagnosed as adults. The two most burdensome symptoms according to patients are debilitating fatigue and progressive muscle weakness. For some, the disease brings a shortened lifespan. Several measures have been taken to facilitate drug development in rare disease (e.g. the Orphan Drug Act), but there are no approved medicines for systemic mitochondrial disease.

‘Illuminate Tomorrow: Revitalise your energy’ is the theme of World Mitochondrial Disease Week 2024, taking place on September 16 – 22. During the week, Abliva will share videos focused on the disease, the important role that patients play in drug development, and the company’s own drug development programs. Abliva will also talk about the positive readout of the interim analysis of the FALCON study, a potentially registrational study evaluating the safety and efficacy of KL1333 in adult mitochondrial disease patients who experience debilitating fatigue and muscle weakness.

Starting today, September 16, Abliva’s videos will be posted daily on the company’s website, https://abliva.com/world-mitochondrial-disease-week-2024/, YouTube channel, and LinkedIn page.

About primary mitochondrial disease

Primary mitochondrial disease affects the ability of cells to convert energy. The disease can manifest itself very differently depending on the organs impacted and the number of dysfunctional mitochondria in that organ. Historically viewed as clinical syndromes, our knowledge about the various mutations underlying mitochondrial disease has increased, improving our ability to identify and treat these patients. It is estimated that 1 in 5,000 people have primary mitochondrial disease. It often presents in early childhood and leads to severe symptoms, such as mental retardation, fatigue, myopathy, heart failure and rhythm disturbances, diabetes, movement disorders, stroke-like episodes, and epileptic seizures.

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit www.abliva.com . Subscribe to our news and follow us on LinkedIn and YouTube.

Stay up to date with our newsletter